OncoGenex Pharmaceuticals, Inc.
) recently announced the commencement of an
investigator-sponsored phase II trial, Rainer, on its oncology
We note that OncoGenex is evaluating apatorsen (OGX-427) in
) Abraxane and Gemzar in patients with previously untreated
metastatic pancreatic cancer.
The randomized, placebo-controlled study will randomize 130
patients to receive either apatorsen or placebo in combination
with Abraxane and Gemzar therapy. The primary end point is
Other end points include progression-free survival (PFS),
tumor response rates, safety, and tolerability among others.
OncoGenex estimates approximately 45,000 people will be
diagnosed with pancreatic cancer in the U.S. leading to
approximately 38,500 deaths in 2013. Hence, a positive result
from the trial will be a significant step forward for OncoGenex
to come up with a potential treatment option for pancreatic
Earlier in the month, OncoGenex initiated another phase II
trial, Spruce, on apatorsen. OncoGenex is evaluating apatorsen
for the treatment of previously untreated advanced non-squamous
non-small cell lung cancer (NSCLC).
The trials are part of the ORCA (Ongoing Studies Evaluating
Treatment Resistance in CAncer) program.
We remind investors that the most advanced candidate in
OncoGenex's pipeline is custirsen (phase III) under evaluation
for the treatment of metastatic castrate-resistant prostate
cancer in men and also for the treatment of patients with
advanced, unresectable non-small cell lung cancer.
OncoGenex has a global collaboration and license agreement
Teva Pharmaceutical Industries Ltd.
) to develop and commercialize the candidate.
The successful development and commercialization of custirsen
will be a major positive for OncoGenex. OncoGenex currently has
no approved drug in its portfolio. We expect investor focus to
remain on custirsen.
OncoGenex currently carries a Zacks Rank #3 (Hold). Right now,
) looks attractive with a Zacks Rank #2 (Buy).
CELGENE CORP (CELG): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
ONCOGENEX PHARM (OGXI): Free Stock Analysis
TEVA PHARM ADR (TEVA): Free Stock Analysis
To read this article on Zacks.com click here.